INDIVIOR PLC 近日发布业绩展望,公司预计到2026年,其核心产品Sublocade的配药单位增长率将维持在中等双位数水平。这一增长预期凸显了该药物在市场渗透和临床接受度方面的持续动力。
作为专注于成瘾治疗领域的制药企业,INDIVIOR PLC 通过Sublocade(丁丙诺啡缓释注射剂)为阿片类使用障碍患者提供月度治疗方案。公司对中期增长目标的确认,反映出其对产品商业化策略及市场需求韧性的信心。
INDIVIOR PLC 近日发布业绩展望,公司预计到2026年,其核心产品Sublocade的配药单位增长率将维持在中等双位数水平。这一增长预期凸显了该药物在市场渗透和临床接受度方面的持续动力。
作为专注于成瘾治疗领域的制药企业,INDIVIOR PLC 通过Sublocade(丁丙诺啡缓释注射剂)为阿片类使用障碍患者提供月度治疗方案。公司对中期增长目标的确认,反映出其对产品商业化策略及市场需求韧性的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.